Upcoming Diabetes Drugs in 2026: GLP-1 & Tirzepatide Generic Manufacturers in India
India's pharmaceutical sector is entering one of its busiest years yet for diabetes care. With more than 100 million people living with diabetes in the country, according to ICMR-INDIAB estimates, the demand for affordable, effective treatment has never been higher. And 2026 is shaping up to be a turning point — GLP-1 receptor agonists and tirzepatide-based therapies, once available mostly to patients in wealthier countries, are moving closer to mass-market pricing thanks to Indian manufacturing capacity. This shift matters because India has long been called the "pharmacy of the world," and diabetes care is where that reputation is being tested most directly right now. If you're a patient, caregiver, healthcare investor, or simply someone tracking pharma trends, understanding which diabetes drug manufacturers in India are leading this race will help you separate real progress from marketing noise. This guide breaks down what's actually happening with GLP-1 a...